Skip to search formSkip to main contentSkip to account menu

ECOG Performance Status 0

Known as: ECOG 0 
Fully active, able to carry on all pre-disease performance without restriction.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
4CPS-126 Effectiveness and safety of nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas in a real-world setting
Background Nab-paclitaxel was approved for the treatment of metastatic adenocarcinoma of pancreas (mPAC), as a first treatment in… 
2018
2018
Outcome following second allogeneic hematopoietic cell transplantation: A single‐center experience
Second allogeneic hematopoietic cell transplantation (HCT) may be indicated following relapse or graft failure following first… 
2017
2017
“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.
3533Background: FOLFOXIRI/Bevacizumab (Bev) is superior to FOLFIRI/Bev in the TRIBE trial (F Loupakis, NEJM 2014). The CHARTA… 
2013
2013
Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML
Acute myeloid leukemia (AML) carries a dismal prognosis in older patients, with median survival 8-12 months and especially poor… 
2010
2010
ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
4556 Background: Eribulin mesylate (E7389), a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits… 
2009
2009
Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based…
8028 Background: SCLC presents as ED-SCLC in 60%-70% of patients (pts). AMR, a synthetic anthracycline, is approved for these pts… 
2006
2006
Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies.
13005 Background: AMG 706 is an investigational, oral, multi-kinase inhibitor with both antiangiogenic and direct antitumor… 
2006
2006
A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data.
13001 Background: Pertuzumab (P), a humanized HER2 antibody, represents a new class of targeted agents called HER dimerization… 
2004
2004
Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC).
3517 Background: Bevacizumab [Avastin (BV)], a recombinant humanized monoclonal antibody against VEGF, significantly prolongs… 
1989
1989
Regression analyses of prognostic factors in metastatic malignant melanoma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)